MannKind (NASDAQ:MNKD) Stock Rating Lowered by Wall Street Zen

MannKind (NASDAQ:MNKD) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

A number of other equities analysts have also recently issued reports on MNKD. Wells Fargo & Company dropped their price objective on MannKind from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Friday. Truist Financial set a $9.00 target price on shares of MannKind in a research note on Monday, November 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of MannKind in a research note on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of MannKind in a research report on Wednesday. Finally, Leerink Partners began coverage on shares of MannKind in a research note on Thursday, November 13th. They issued an “outperform” rating and a $7.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.21.

MannKind Trading Up 1.2%

Shares of MNKD opened at $3.28 on Friday. The company’s fifty day simple moving average is $5.55 and its 200-day simple moving average is $5.35. The company has a market cap of $1.01 billion, a P/E ratio of 164.08 and a beta of 0.84. MannKind has a twelve month low of $2.93 and a twelve month high of $6.51.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.04). The firm had revenue of $111.96 million for the quarter, compared to the consensus estimate of $99.85 million. MannKind had a net margin of 1.68% and a negative return on equity of 11.12%. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.03 earnings per share. Analysts predict that MannKind will post 0.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Stuart A. Tross sold 47,006 shares of MannKind stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $6.33, for a total transaction of $297,547.98. Following the transaction, the insider directly owned 985,007 shares of the company’s stock, valued at $6,235,094.31. This trade represents a 4.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Michael Castagna sold 107,920 shares of the company’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $5.57, for a total value of $601,114.40. Following the sale, the chief executive officer owned 2,504,792 shares of the company’s stock, valued at approximately $13,951,691.44. This represents a 4.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 262,846 shares of company stock worth $1,546,840. Insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On MannKind

Several institutional investors and hedge funds have recently added to or reduced their stakes in MNKD. Caitong International Asset Management Co. Ltd raised its stake in MannKind by 108.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 2,927 shares during the last quarter. International Assets Investment Management LLC purchased a new position in shares of MannKind in the fourth quarter worth about $45,000. Huntington National Bank raised its stake in shares of MannKind by 420.0% in the fourth quarter. Huntington National Bank now owns 10,400 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 8,400 shares during the last quarter. Burkett Financial Services LLC acquired a new stake in shares of MannKind during the fourth quarter worth about $59,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in MannKind in the fourth quarter valued at approximately $60,000. Hedge funds and other institutional investors own 49.55% of the company’s stock.

Key Stories Impacting MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Revenue beat and growth outlook — MannKind reported Q4 revenue of about $112M (+46% YoY) and management outlined a roughly $450M 2026 revenue run‑rate while preparing an Afrezza pediatric launch, which supports longer‑term upside. MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst keeps “overweight” despite cut — Wells Fargo trimmed its price target from $8 to $7 but maintained an overweight rating, signaling continued analyst conviction in upside even after the EPS miss. Wells Fargo price target note
• Neutral Sentiment: Heavy options activity — Reports show large volume of call option purchases in MNKD, which can amplify intraday moves and reflects some speculative bullish positioning but is not a guarantee of sustained upside. Investors Purchase Large Volume of MannKind Call Options
• Neutral Sentiment: Mixed metric readouts — Analysts note revenue comfortably beat estimates while EPS missed (-$0.05 vs. -$0.01 expected), leaving valuation/forward EPS expectations in flux—important context but mixed for immediate direction. MannKind Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: EPS miss and unexpected quarterly loss drove the sell‑off — The bottom‑line shortfall led to a sharp intraday drop and a 52‑week low as investors reacted negatively to the EPS miss despite revenue growth. Why MannKind Stock Tumbled on Thursday
• Negative Sentiment: RBC cut price target sharply — Royal Bank of Canada cut its target from $7.50 to $3.50 (sector perform), reducing near‑term analyst support and adding selling pressure. RBC rating/price target note
• Negative Sentiment: Broader biotech weakness — A sector‑wide pullback (“biotech bloodbath”) this week has dragged MNKD along with peers, amplifying downside from company‑specific negatives. Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
• Negative Sentiment: Competitive risk flagged — News that United Therapeutics is considering a new treprostinil formulation pressured MannKind (and peers), introducing potential product/market risk for inhaled/treprostinil formulations. United Therapeutics mulls new treprostinil formulation

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.